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The MSH6 gene in collaboration with MSH2,
MLH1, MSH3, PMS1 and PMS2 genes is involved in
one of the systems repairing the errors that arise during
DNA replication, called the “methyl directed mismatch
repair” system [1-3]. hMLH1 and hMSH2 mutations
give rise most frequently to the classical Lynch syndrome
(HNPCC) [4-6]. hMSH6 mutations often occur in
clinically less typical HNPCC families, that do not fulfil
the Amsterdam criteria [7-11]. So far more than 200
families with germline hMSH6 mutation have been
described (www.med.ca/MMRvariants).
Characteristic features of families with hMSH6
mutation are:
• higher risk for colorectal cancer (~70% for men and
~30% for females), endometrial cancer (~70%) and
also for ovarian, upper urinary tract, stomach and
breast cancer [12],
• higher incidence of extracolonic cancers, when
compared with HNPCC families [13],
• later age at onset of cancers, e.g. for colorectal
cancer the mean age at diagnosis is ~56 years, for
endometrial cancer ~54 years and for ovarian
cancer ~49 years [12, 13],
• frequent left-sided localization of colorectal cancer [9].
The prevalence of hMSH6 constitutional mutations
in families that fulfil the Amsterdam criteria is about 
5-10% [8, 9].
Because the frequency of hMSH6 mutations in other
groups is not precisely determined, we recommend the
following diagnostic procedure for hMSH6 mutation
detection:
• selection of families with colorectal, endometrial,
ovarian, urinary tract and/or stomach, breast cancer
aggregation,
• immunohistochemical analysis (IHC) of hMSH6
protein expression in tumour colorectal or endometrial
tissue [14-16],
•  in cases of hMSH6-negative tumours, DHPLC/
sequencing of the coding regions of the hMSH6
gene.
Among the reported hMSH6 mutations about 30
are recurrent, i.e. they are detected in more than one
family [17-19]. Probably in the near future diagnostic
tests will be described to allow cheap, simple and fast
detection of mutations showing a “founder effect”
characteristic for particular ethnic groups.
S Su ur rv ve ei il ll la an nc ce e   p pr ro ot to oc co ol l
As yet a suitable surveillance programme in hMSH6
families based on prospective family trials is not
available. In our centre we offer the following surveillance
protocol:
• colorectal cancer – colonoscopy every 2 to 3 years
beginning at least 15 years before the earliest age
of onset in the family,
• endometrial cancer – annual transvaginal ultrasound
scan starting at least 15 years before the earliest age
of onset in the family,
• screening for other cancers depending on the tumour
spectrum in the family.
S Su ur rg gi ic ca al l   m ma an na ag ge em me en nt t
Because of the described higher risk of developing
multiple (synchronous and metachronous) cancers and
also endometrial cancer in females after age of 50 years
in  hMSH6 mutation carriers [12, 17, 20], it is
recommended to take into consideration surgical
treatment similar to that for patients with CRC associated
with Lynch syndrome, i.e. colectomy with ileorectal
anastomosis, extended by prophylactic hysterectomy
and oophorectomy for women over 50 years old.
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